Commentary

Video

Dr Shields on Key ADRIATIC Trial Data With Adjuvant Durvalumab in LS-SCLC

Misty D. Shields, MD, PhD, discusses the implications of the ADRIATIC trial of adjuvant therapy with durvalumab vs placebo in patients with LS-SCLC.

Misty D. Shields, MD, PhD, assistant professor, clinical medicine, Department of Medicine, Division of Hematology/Oncology, Indiana University (IU) School of Medicine; and associate member, Experimental and Developmental Therapeutics, IU Melvin and Bren Simon Comprehensive Cancer Center, discusses the implications of the phase 3 ADRIATIC trial (NCT03703297) investigating adjuvant durvalumab (Imfinzi) vs placebo in patients with limited-stage small cell lung cancer.

Related Videos
Howard Colman, MD, PhD, Jan M. Huntsman Presidential Professor, Department of Neurosurgery, member, Brain Tumor Research Team, and leader, Center for Neurologic Cancers, Huntsman Cancer Institute, University of Utah
Kathleen N. Moore, MD, MS
Rona Yaeger, MD
 PER® International Symposium on Melanoma and Other Cutaneous Malignancies
Robert
Charles B. Nguyen, MD
YI LIN, MD, PHD
Dr Fakih on the FDA Approval of Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC
Al Malki
Ian Krop MD, PhD